# Directorate General of Medical Supplies

**Decisions of CDC meeting No: 12 dated 11/11/2014**

<table>
<thead>
<tr>
<th>Sr</th>
<th>Item Description</th>
<th>Request/Supplier</th>
<th>CDC Decision</th>
</tr>
</thead>
</table>
| 13 | Bacillus Calmette-Geruin (BCG) 81mg vial (01VC/388) | Urology Dept, Royal Hospital | Approved  
- As per the protocol for Bladder instillation in Carcinoma in situ, Superficial grade 3, Bladder Tumour  
- To be prescribed by Specialists (Urology) and above |
| 14 | Disodium ethylenediamine tetra acetic acid (EDTA) 3% mixture | Ophthalmology, Al Nahdha Hospital | Approved  
- Al Nahdha Hospital to provide information regarding the required pharmaceutical dosage form |
| 15 | Misoprostol 200mg tablets (03/47054) | DGMS | Already approved  
- CDC confirmed and requested for activation of its previous decision dated 01/04/2009 stating as follows:  
  - Restricted for Hospital Use Only  
  - To suspend its marketing from private pharmacies to avoid misuse  
  - Restricted for Medically recommended abortion cases by Sr.Specialists and above in Government and Private Hospitals.  
  - For MOH Hospitals - To be used for Inpatients only. In exceptional cases like bed shortage, the next doses to be issued for use as outpatient.  
  - For Private Sector - To be used in Hospitals where Obs & Gyn Dept is functioning and to be restricted for Inpatients only. |
| 16 | Human Prothrombin complex injection | Chairman, Emergency Medicine Services Development Committee | Approved  
- As Anti-bleeding agent For Emergency Depts at Tertiary/Secondary Care Hospitals |
| 17 | Digoxin specific Antibody Fragments IV (Digifab) | Chairman, Emergency Medicine Services Development Committee | Approved  
- As Antidote in the ICU at Tertiary/Secondary Care Hospitals |
| 18 | Actretin patient consent form | DGMS | Approved to design and distribute |
| 19 | Apracodionidine 0.5% eye drops | Ophthalmology, Al Nahdha Hospital | Already approved in CDC meeting 11/2014  
- The submitted protocol is approved |
| 20 | Hydroxethyl starch (average molecular weight 200,000) 6% in Sodium Chloride intravenous infusion 0.9% 500 ml. | DGMS letter about EMEA report recommending to suspend marketing authorization | To continue the use for the treatment of Hypovolemia caused by Acute blood loss. |
| 21 | Micronized Fenofibrate 145-200mg tablets (03-2762) | DGMS | Approved  
- To replace 300mg standard formulation as micronized formulation is more rapidly and completely absorbed |